🎗️ Ovarian / Tubal / Peritoneal Cancer FIGO 2014 Stage
UseStaging and management direction for ovarian/tubal/peritoneal cancer, which share a single FIGO system.
Loading calculator…
SourcePrat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fal…
Runs locally in your browser (no PHI uploaded). For licensed clinicians — not a substitute for clinical judgement.
Stored on this device for revisit reminders
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Scene next step
📋gyn oncoOpen scene pack →Related scores
Matching pathway
🧭cervical_ca_mriOpen pathway →Score + version; reference only — not a substitute for care · no HIS write
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Clinical takeaway
Splenic/hepatic capsule (surface) disease is IIIC, but hepatic/splenic parenchymal metastasis is IVB — a common staging pitfall.
When to use
Staging and management direction for ovarian/tubal/peritoneal cancer, which share a single FIGO system.
How it works
I confined to gonads (IA/IB/IC1 intraoperative rupture/IC2 pre-op rupture or surface/IC3 washings positive); II pelvic extension (IIA/IIB); III nodes or extrapelvic peritoneum (IIIA1 i ≤ 10 / ii > 10 mm, IIIA2 micro, IIIB ≤ 2 cm, IIIC > 2 cm); IVA pleural cytology, IVB parenchymal/extra-abdominal.
Key points
- Splenic/hepatic capsule (surface) disease is IIIC, but hepatic/splenic parenchymal metastasis is IVB — a common staging pitfall.
- Stage IC is split by mechanism: IC1 surgical spill, IC2 pre-operative rupture or surface tumour, IC3 positive ascites/washings.
- Early disease has comprehensive staging surgery ± platinum/taxane chemotherapy; advanced disease has cytoreduction aiming for no gross residual.
- BRCA-mutant / HRD-positive advanced disease is offered PARP-inhibitor maintenance.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| When confined to ovary/tube | IC1 — intraoperative rupture (surgical spill) |
|---|---|
| Pelvic extension (below pelvic brim) | IIA — uterus/tube/ovary |
| Retroperitoneal nodes (nodes only, no peritoneal spread) | IIIA1(i) — ≤ 10 mm |
| Extrapelvic peritoneal spread | IIIA2 — microscopic extrapelvic peritoneum |
| Distant metastasis | IVA — pleural effusion, cytology positive |
→FIGO stageStage IVA
- FIGO 2014 stage：Stage IVA (pleural effusion, cytology positive)
- Management direction：Cytoreductive surgery (aim for optimal / no gross residual) + platinum/paclitaxel chemotherapy ± bevacizumab; BRCA-mutant / HRD-positive → PARP inhibitor maintenance; bulky or unresectable advanced disease may have neoadjuvant chemotherapy then interval cytoreduction
- Notes：Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB
| When confined to ovary/tube | IA — unilateral, capsule intact, no surface tumour, washings negative |
|---|---|
| Pelvic extension (below pelvic brim) | None |
| Retroperitoneal nodes (nodes only, no peritoneal spread) | None |
| Extrapelvic peritoneal spread | None |
| Distant metastasis | None |
→FIGO stageStage IA
- FIGO 2014 stage：Stage IA (unilateral, capsule intact, washings negative)
- Management direction：Comprehensive staging surgery (total hysterectomy + BSO + omentectomy + peritoneal biopsies + pelvic/para-aortic node assessment ± washings); IA/IB low-grade may be observed, IC or high-grade → platinum + paclitaxel adjuvant chemotherapy; fertility-sparing may be considered in selected early disease
- Notes：Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Ovarian / Tubal / Peritoneal Cancer FIGO 2014 Stage?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Ovarian / Tubal / Peritoneal Cancer FIGO 2014 Stage upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is Ovarian / Tubal / Peritoneal Cancer FIGO 2014 Stage calculated in practice? Can you show a worked example?
- Inputs: When confined to ovary/tube IC1 — intraoperative rupture (surgical spill), Pelvic extension (below pelvic brim) IIA — uterus/tube/ovary, Retroperitoneal nodes (nodes only, no peritoneal spread) IIIA1(i) — ≤ 10 mm, Extrapelvic peritoneal spread IIIA2 — microscopic extrapelvic peritoneum, Distant metastasis IVA — pleural effusion, cytology positive → Result: FIGO stage Stage IVA（FIGO 2014 stage: Stage IVA (pleural effusion, cytology positive), Management direction: Cytoreductive surgery (aim for optimal / no gross residual) + platinum/paclitaxel chemotherapy ± bevacizumab; BRCA-mutant / HRD-positive → PARP inhibitor maintenance; bulky or unresectable advanced disease may have neoadjuvant chemotherapy then interval cytoreduction, Notes: Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB） Inputs: When confined to ovary/tube IA — unilateral, capsule intact, no surface tumour, washings negative, Pelvic extension (below pelvic brim) None, Retroperitoneal nodes (nodes only, no peritoneal spread) None, Extrapelvic peritoneal spread None, Distant metastasis None → Result: FIGO stage Stage IA（FIGO 2014 stage: Stage IA (unilateral, capsule intact, washings negative), Management direction: Comprehensive staging surgery (total hysterectomy + BSO + omentectomy + peritoneal biopsies + pelvic/para-aortic node assessment ± washings); IA/IB low-grade may be observed, IC or high-grade → platinum + paclitaxel adjuvant chemotherapy; fertility-sparing may be considered in selected early disease, Notes: Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB）